Amyloid-β Peptide Triggers Membrane Remodeling in Supported Lipid Bilayers Depending on Their Hydrophobic Thickness

Langmuir ◽  
2018 ◽  
Vol 34 (32) ◽  
pp. 9548-9560 ◽  
Author(s):  
Sigalit Meker ◽  
Hokyun Chin ◽  
Tun Naw Sut ◽  
Nam-Joon Cho
2013 ◽  
Vol 104 (2) ◽  
pp. 239a
Author(s):  
Jason O. Matos ◽  
Jeffrey Bulson ◽  
Suren A. Tatulian

2004 ◽  
Vol 86 (6) ◽  
pp. 3585-3597 ◽  
Author(s):  
David L. Mobley ◽  
Daniel L. Cox ◽  
Rajiv R.P. Singh ◽  
Michael W. Maddox ◽  
Marjorie L. Longo

2016 ◽  
Vol 113 (39) ◽  
pp. 10866-10871 ◽  
Author(s):  
Montserrat Serra-Batiste ◽  
Martí Ninot-Pedrosa ◽  
Mariam Bayoumi ◽  
Margarida Gairí ◽  
Giovanni Maglia ◽  
...  

The formation of amyloid-β peptide (Aβ) oligomers at the cellular membrane is considered to be a crucial process underlying neurotoxicity in Alzheimer’s disease (AD). Therefore, it is critical to characterize the oligomers that form within a membrane environment. To contribute to this characterization, we have applied strategies widely used to examine the structure of membrane proteins to study the two major Aβ variants, Aβ40 and Aβ42. Accordingly, various types of detergent micelles were extensively screened to identify one that preserved the properties of Aβ in lipid environments—namely the formation of oligomers that function as pores. Remarkably, under the optimized detergent micelle conditions, Aβ40 and Aβ42 showed different behavior. Aβ40 aggregated into amyloid fibrils, whereas Aβ42 assembled into oligomers that inserted into lipid bilayers as well-defined pores and adopted a specific structure with characteristics of a β-barrel arrangement that we named β-barrel pore-forming Aβ42 oligomers (βPFOsAβ42). Because Aβ42, relative to Aβ40, has a more prominent role in AD, the higher propensity of Aβ42 to form βPFOs constitutes an indication of their relevance in AD. Moreover, because βPFOsAβ42 adopt a specific structure, this property offers an unprecedented opportunity for testing a hypothesis regarding the involvement of βPFOs and, more generally, membrane-associated Aβ oligomers in AD.


Langmuir ◽  
2017 ◽  
Vol 33 (51) ◽  
pp. 14756-14765 ◽  
Author(s):  
Lisa M. Kawakami ◽  
Bo Kyeong Yoon ◽  
Joshua A. Jackman ◽  
Wolfgang Knoll ◽  
Paul S. Weiss ◽  
...  

Biochemistry ◽  
2003 ◽  
Vol 42 (46) ◽  
pp. 13667-13672 ◽  
Author(s):  
Silvia Dante ◽  
Thomas Hauss ◽  
Norbert A. Dencher

Soft Matter ◽  
2018 ◽  
Vol 14 (47) ◽  
pp. 9609-9618 ◽  
Author(s):  
Galya Staneva ◽  
Nicolas Puff ◽  
Stanislav Stanimirov ◽  
Todor Tochev ◽  
Miglena I. Angelova ◽  
...  

The Alzheimer amyloid β-peptide binds to the liquid-disordered lipid phase and modulates the nanodomain–microdomain size dynamics of raft-mimicking Lo domains in model membranes containing the ganglioside GM1.


Langmuir ◽  
2018 ◽  
Vol 34 (28) ◽  
pp. 8408-8414 ◽  
Author(s):  
Mengting Yang ◽  
Kang Wang ◽  
Jiake Lin ◽  
Liqun Wang ◽  
Feng Wei ◽  
...  

2014 ◽  
Vol 56 ◽  
pp. 99-110 ◽  
Author(s):  
David Allsop ◽  
Jennifer Mayes

One of the hallmarks of AD (Alzheimer's disease) is the formation of senile plaques in the brain, which contain fibrils composed of Aβ (amyloid β-peptide). According to the ‘amyloid cascade’ hypothesis, the aggregation of Aβ initiates a sequence of events leading to the formation of neurofibrillary tangles, neurodegeneration, and on to the main symptom of dementia. However, emphasis has now shifted away from fibrillar forms of Aβ and towards smaller and more soluble ‘oligomers’ as the main culprit in AD. The present chapter commences with a brief introduction to the disease and its current treatment, and then focuses on the formation of Aβ from the APP (amyloid precursor protein), the genetics of early-onset AD, which has provided strong support for the amyloid cascade hypothesis, and then on the development of new drugs aimed at reducing the load of cerebral Aβ, which is still the main hope for providing a more effective treatment for AD in the future.


2014 ◽  
Vol 56 ◽  
pp. 69-83 ◽  
Author(s):  
Ko-Fan Chen ◽  
Damian C. Crowther

The formation of amyloid aggregates is a feature of most, if not all, polypeptide chains. In vivo modelling of this process has been undertaken in the fruitfly Drosophila melanogaster with remarkable success. Models of both neurological and systemic amyloid diseases have been generated and have informed our understanding of disease pathogenesis in two main ways. First, the toxic amyloid species have been at least partially characterized, for example in the case of the Aβ (amyloid β-peptide) associated with Alzheimer's disease. Secondly, the genetic underpinning of model disease-linked phenotypes has been characterized for a number of neurodegenerative disorders. The current challenge is to integrate our understanding of disease-linked processes in the fly with our growing knowledge of human disease, for the benefit of patients.


Sign in / Sign up

Export Citation Format

Share Document